Genetic Analysis AS (NGM: GEAN)
Sweden flag Sweden · Delayed Price · Currency is SEK · Price in NOK
0.440
+0.031 (7.58%)
At close: Nov 22, 2024

Genetic Analysis AS Company Description

Genetic Analysis AS, a science-based diagnostic company, develops diagnostic solutions for human microbiome market.

It offers GA-map Dysbiosis Test Lx, a molecular assay for profiling the gut microbiota to identify and characterize dysbiosis for treating patients with Irritable Bowel Syndrome, Inflammatory Bowel Disease, diabetes type 2, gut disorder, lifestyle diseases, and leaky-gut syndrome; GA-map COVID-19 Fecal Test Kit, a qualitative real time standardized PCR test for the detection of the 2019 novel coronavirus RNA in stool samples; GA-map Dysbiosis Test reagent kit, a CE-IVD documented test, which is a software that performs QC on the run file, calculates the dysbiosis index score and abundance table, and converts sample result into reports; and GA-map Covid fecal test reagent kit, a CE-IVD documented test to detect SARS-CoV-2 in fecal samples.

The company was founded in 2008 and is headquartered in Oslo, Norway.

Genetic Analysis AS
Country Norway
Founded 2008
Industry In Vitro and In Vivo Diagnostic Substances
Employees 21
CEO Ronny Hermansen

Contact Details

Address:
Kabelgata 8
Oslo, 0580
Norway
Phone 47 48 32 16 10
Website genetic-analysis.com

Stock Details

Ticker Symbol GEAN
Exchange Nordic Growth Market
Fiscal Year January - December
Reporting Currency NOK
SIC Code 2835

Key Executives

Name Position
Ronny Hermansen Chief Executive Officer
Lars Tiller Chief Operating Officer